{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"49"}],"units":"Participants"}],"description":"The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA and CRP. The equation used to calculate the SDAI:\n\nSDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \\* 100","groups":[{"description":"Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG000","title":"1 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG001","title":"2 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG002","title":"4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG003","title":"8 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.","id":"OG004","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All participants who received any amount of study drug in Part A.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 weeks","title":"Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}